)
)
Lucid Diagnostics Investor Relations Material
Latest events
Q3 2024
Lucid Diagnostics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Lucid Diagnostics Inc
Access all reports
Lucid Diagnostics Inc. is a medical diagnostics company focused on the early detection of esophageal precancer and cancer. The company develops and commercializes diagnostic tests that aim to identify patients at risk of esophageal adenocarcinoma, a cancer often associated with gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Lucid's lead product, the EsoCheck diagnostic device, is designed to collect esophageal cells in a non-invasive procedure for further analysis using its EsoGuard test, which detects genetic changes associated with cancer risk. The company’s technology provides a less invasive alternative to traditional diagnostic methods like endoscopy. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
LUCD
Country
🇺🇸 United States